# US 2001/0025025 A1 · Novel process for the preparation of cyclosporin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025025 A1
- Document ID: US20010025025A1
- Status: Published application
- Kind: A1
- Application number: 09/742,008
- Filed: 2000-12-22
- Published: 2001-09-27
- Earliest claimed: 1998-06-22
- Assignees: Aventis Pharma S.A.
- Inventors: Christian Viskov
- Web page: https://patentgrep.com/patent/US20010025025A1

## CPC

- C07K 7/645: {Cyclosporins; Related peptides}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/12: Schistosomicides
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position a and/or any other acid group capable of deprotonation which are optionally deprotonated or in protected form.

## Claims

### Claim 1

A process for preparing a polyanion for use as an intermediate in the preparation of a cyclosporin derivative, said process comprising treating a cyclosporin with a hexamethyldisilazane metal salt.

### Claim 2 (depends on 1)

The process according to claim 1, wherein said process occurs in the presence of a metal halide.

### Claim 3 (depends on 1)

The process according to claim 1, in which said polyanion has the formula: 12
in which 13
is a cyclosporin in which one or more hydroxyl groups and optionally one or more non-methylated nitrogen atoms at the a position and optionally any other deprotonatable acidic group are optionally deprotonated or in the protected form.

### Claim 4 (depends on 1)

The process according to claim 1, in which said polyanion has the formula: 14
in which:
i) the radicals R1, R2, and R4 to R11, and Z1, Z2, and Z4 to Z11 are defined as for cyclosporin A; or
ii) the radicals R1, R2, and R4 to R11, and Z1, Z2, and Z4 to Z11 are defined as for cyclosporin A, with the exception of R4 and Z4, which are defined so as to have, at the 4-position, the amino acid 4′-hydroxy-methylleucine; or
iii) the radicals R2 and R5 to R11, and Z2 and Z5 to Z11 are defined as for cyclosporin A; and
Z1 is a methyl group and R1 has the formula: 15
in which R is a radical of formula —CH2—CH═CH—CH2—R′, in which R′ is an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkyl phenylthio, hydroxyalkylphenyloxy, nitrophenylamino, or 2-oxopyrimidin-1-yl radical; or
R is a radical of formula —CH2—S-Alk in which Alk, is an alkyl group; and
Z4and R4 are radicals such that there is, at the 4-position, an amino acid methylleucine or 4′-hydroxy-methylleucine; or
iv)
Z1 and R1 are radicals such that there is, at the 1-position, a substituted homothreonine of formula:
Ri—CH2CH(CH3)—CH(OH)—CH(NHCH3)—COOH (IIIb)
in which Ri is n-propyl or propenyl; and
R2 and Z2 are radicals such that there is, at the 2-position, α-aminobutyric acid, valine, norvaline, or threonine; and
R4 and Z4 are radicals such that there is, at the 4-position, N-methyl-γ-hydroxyleucine or N-methyl-γ-acetyloxyleucine; and
R5 and Z5 are radicals such that there is, at the 5-position, valine; and
R6, Z6, R9, Z9, R10, and Z10 are radicals such that there is, at the 6-, 9-, and 10-positions, N-methylleucine; and
Z7 and R7 are radicals such that there is, at the 7-position, alanine; and
Z8 and R8 are radicals such that there is, at the 8-position, D-alanine or D-serine; and
Z11 and R11 are radicals such that there is, at the 11-position, N-methylvaline; or
v) Z1 and R1 are radicals such that there is, at the 1-position, an methyl (4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine (MeBmt) radical or a radical having the formula: 16
in which Rj is a hydrogen atom or a lower alkyl group, a lower alkenyl, a lower haloalkyl, an aryl, a lower alkyloxy, an alkoxyC1-6alkyl, a hydroxymethyl, a lower alkylthio, an alkylthioC1-6alkyl, a C1-6 mercaptoalkyl, or a heteroaryl;
it being possible for the aryl and heteroaryl groups to be substituted with one or more functional groups chosen from: C1-6 alkyl; C1-6 alkanoyl; C1-6, haloalkyl; halo; cyano; C1-3 hydroxyalkyl; C1-6 alkyloxy; C1-6 alkyl-S(O)n, where n=0, 1, or 2; NRbCORc, in which Rb and Rc independently are H or a C1-6 alkyl, —NO2, —NRbRc, —ORb, —CONRbRc, —CORb, —NRbCONRbRc, NRbCORc, —OCORb, —SCORb, or —OCH2O—; and
Ra is a lower alkyl; and
Z1 is a lower alkyl, a lower phenylalkyl, or an aryl; and
X is S, SO, SO2, O, or NRb; and
Z2 and R2 are radicals such that there is, at the 2-position, the amino acid L-2-aminobutyric acid, Norvaline, L-Thr, or the same amino acid as at the 1-position; and
Z4 and R4 are radicals such that there is, at the 4-position, the amino acid N-methyl-L-leucine; and
Z5 and R5 are radicals such that there is, at the 5-position, the amino acid L-valine or norvaline; and
Z6 and R6 are radicals such that there is, at the 6-position, the amino acid N-methyl-L-leucine; and
Z7 and R7 are radicals such that there is, at the 7-position, the amino acid L-alanine, L-2-aminobutyric acid, or L-phenylalanine; and
Z8 and R8 are radicals such that there is, at the 8-position, the amino acid D-alanine or L-alanine; and
Z9 and R9 are radicals such that there is, at the 9-position, the amino acid N-methyl-L-leucine or N-methyl-L-valine; and
Z10 and R10 are radicals such that there is, at the 10-position, the amino acid N-methyl-L-leucine or L-leucine; and
Z11 and R11 are radicals such that there is, at the 11-position, the amino acid N-methyl-L-valine, L-valine, or L-2-aminobutyric acid; or
vi) the radicals R4 to R11 and Z4 to Z11 are defined as for cyclosporin A; and
Z1 and R1 are radicals such that there is, at the 1-position, the amino acid MeBmt or dihydro-MeBmt; and
Z2 and R2 are radicals such that there is, at the 2-position, the amino acid α-aminobutyric acid, threonine, valine, or norvaline; or
vii) the radicals R7 to R11 and Z7 to Z11 are defined as for cyclosporin A; and
Z1 and R1 are radicals such that there is, at the 1-position, the amino acid MeBmt, dihydro-MeBmt , or 8′-hydroxy-MeBmt; and
Z2 and R2 are radicals such that there is, at the 2-position, the amino acid α-aminobutyric acid, valine, threonine, norvaline, or MeOThr; and
Z4 and R4are radicals such that there is, at the 4- position, the amino acid methylleucine, γ-hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle, or MeaThr; and
Z5 and R5 are radicals such that there is, at the 5-position, the amino acid valine, Leu, MeVal, or methylleucine; and
Z6 and R6 are radicals such that there is, at the 6-position, the amino acid methylleucine, γ-hydroxy-MeLeu, or MeAla;
provided that, when R4 and Z4 are MeLeu, then R5 and Z5 are MeVal or methylleucine, or R1 and Z1 are 8′-hydroxy-MeBmt; or
viii) the radicals R1, R2, and R4 to R11, and Z1, Z2, and Z4 to Z11 define a cyclosporin in which the 3′ carbon of the residue at the 1-position or the β carbon of the residue at the 2-position is substituted by O-acyl or oxo; and
Z1 and R1 are radicals such that there is, at the 1-position, a residue of formula 17
in which —V—W— is CH2—CH2 or trans CH═CH and ACYL1 is an acyl group; and
Z2 and R2 are radicals such that there is, at the 2-position, an amino acid α-aminobutyric acid, valine, threonine, norvaline, or a β-O-acylated α-amino acid; and
Z5 and R5 are radicals such that there is, at the 5-position, an amino acid valine or norvaline when there is simultaneously an amino acid norvaline at the 2-position; and
Z8 and R8 are radicals such that there is, at the 8-position, an amino acid D-alanine or a β-O-acylated or β-hydroxylated α-amino acid having the D configuration; and
the radicals at the 4-, 6-, 7-, and 9- to 11-positions are defined as for cyclosporin A; and
one or more hydroxyl groups and optionally one or more non-methylated nitrogen atoms at the α position and optionally any other deprotonatable acidic group present in said formula (II) are optionally deprotonated or in the protected form.

### Claim 5 (depends on 1)

The process according to claim 1, in which said hexamethyldisilazane metal salt is a hexamethyldisilazane alkali metal salt.

### Claim 6 (depends on 5)

A process according to claim 5, in which said hexamethyldisilazane metal salt is chosen from the hexamethyldisilazane lithium salt, the hexamethyldisilazane sodium salt, and the hexamethyldisilazane potassium salt.

### Claim 7 (depends on 6)

The process according to claim 6, in which said hexamethyldisilazane metal salt is used in an amount ranging from 20 to 30 molar equivalents.

### Claim 8 (depends on 2)

The process according to claim 2, in which, when the treatment of the cyclosporin is carried out in the presence of a metal halide, said metal halide is chosen from lithium chloride, caesium chloride, caesium fluoride, cuprous chloride, and mercuric chloride.

### Claim 9 (depends on 8)

The process according to claim 8, in which, when said metal halide is caesium chloride or lithium chloride, it is used in an amount ranging from 2 to 8 molar equivalents.

### Claim 10 (depends on 9)

The process according to claim 9, in which the treatment of the cyclosporin is carried out in an aliphatic or cyclic ether, an aromatic hydrocarbon, or a mixture of these solvents.

### Claim 11 (depends on 10)

The process according to claim 10, in which the treatment of the cyclosporin is carried out at a temperature ranging from −40° C. to 0° C.

### Claim 12 (depends on 11)

The process according to claim 11, in which the treatment of the cyclosporin is carried out with a ratio (weight/weight) of cyclosporin involved with respect to the total weight of the solution which is less than or equal to 10%.

### Claim 13

A process for preparing a cyclosporin derivative substituted at the 3-position, said process comprising preparing a polyanion by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide, adding an electrophilic agent to said treated cyclosporin, and, optionally converting the product of said addition to a salt, wherein the hydroxyl radicals, if any, present on the cyclosporin which may possibly interfere with the reaction are protected before said treatment and then the protective radicals are removed, after said treatment.

### Claim 14 (depends on 4, 13)

The process according to claim 13, in which at least one obtained cyclosporin derivative substituted at the 3-position has the formula: 18
in which:
1) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in i) and R3 is a radical —S-Alk-R° in which:
Alk is an alkylene radical comprising from 2 to 6 straight- or branched-chain carbon atoms or a cycloalkylene radical comprising from 3 to 6 carbon atoms; and
R° is
a carboxyl or alkyloxycarbonyl radical; or
an —NG1G2 radical in which G1 and G2, which are identical or different, are each
a hydrogen atom; or
a phenyl, cycloalkyl (C3-6), alkenyl (C2-4), or alkyl radical, each of which is optionally substituted by a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino, or dialkylamino radical; or
a benzyl radical or a saturated or unsaturated heterocyclyl radical comprising 5 or 6 ring members and from 1 to 3 heteroatoms; or
G1 and G2 form, with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising from 4 to 6 ring members which can comprise another heteroatom chosen from nitrogen, oxygen, and sulphur and which is optionally substituted by alkyl, phenyl, or benzyl; or
a radical of formula: 19
in which G1 and G2 are defined as above, G3 is a hydrogen atom or an alkyl radical, and n is an integer from 2 to 4, the alkyl portions or radicals defined above are straight or branched and comprise from 1 to 4 carbon atoms; or
2) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in ii) and R3 is —S—CH3 or a radical —S-Alk-R° in which:
Alk is an alkylene radical comprising from 2 to 6 straight- or branched-chain carbon atoms or a cycloalkylene radical comprising from 3 to 6 carbon atoms; and
R° is
a hydroxyl, carboxyl, or alkyloxycarbonyl radical; or
an —NG1G2 radical or a radical of formula: 20
as defined above; or
the R1 to R11 and Z1 to Z11 radicals are as defined in claim 4 in iii) and R3 a radical of structure —S-Alk-R° in which:
Alk is an alkylene radical comprising from 2 to 6 straight- or branched-chain carbon atoms or a cycloalkylene radical comprising from 3 to 6 carbon atoms; and
R° is
a hydrogen atom or a hydroxyl, carboxyl, or alkyloxycarbonyl radical; or
an —NG1G2 radical in which G1 and G2, which are identical or different, are each
a hydrogen atom; or
a phenyl, cycloalkyl (C3-6), or alkyl radical, each of which is optionally substituted by a halogen atom, or an alkyloxy, alkyloxycarbonyl, amino, alkylamino, or dialkylamino radical; or
a benzyl radical or a saturated or unsaturated heterocyclyl radical comprising 5 or 6 ring members and from 1 to 3 heteroatoms; or
G1 and G2 form, with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle which can comprise another heteroatom chosen from nitrogen, oxygen, and sulphur and which is optionally substituted by alkyl; or
a radical of formula: 21
as defined above; or
4) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in iv) and R3 is a radical chosen from:
straight or branched alkyl (C2-6), alkenyl, or alkynyl, each of which is optionally substituted by a hydroxyl, amino, C1-4 alkylamino, C1-3 dialkylamino, alkyloxy, or acyloxy group;
COOG4 or CONHG4, in which G4 is a straight or branched alkyl comprising from 1 to 4 carbon atoms;
—Y—G5, in which Y is S or O, and G5 is a straight or branched C1 to C4 alkyl, a straight or branched alkenyl, or a straight or branched alkynyl, and in which, if Y is S, G5 can also be an aryl or a heteroaryl;
a halo or cyano group; and
CHG6G7, in which G6 is a hydrogen atom or a methyl, ethyl, or phenyl group and G7 is a hydrogen atom or a hydroxyl, halo, amino, C1-4 alkylamino, C1-4 dialkylamino, acyloxy, t-butoxycarbonylaminoethoxyacetyloxy, or alkyloxycarbonyl group; or
5) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in v) and R3 is a radical such that there is, at the 3-position, an α-(methylmercapto)sarcosyl or N-methyl-D-alanyl residue; or
6) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in vi) and R3 is a C1-6alkyl, haloC1-6alkyl, hydroxy1-6alkyl, mercaptoC1-6alkyl, aminoC1-6alkyl, C2-5alkoxycarbonylamino(C1-4alkyl), nitroC1-6alkyl, cyanoC1-5alkyl, C1-6alkoxy(C1-6alkyl), C1-6alkylthio-(C1-6alkyl), C2-7alkanoyloxy(C1-6alkyl), C2-7diazoalkanoyloxy(C1-6alkyl), carboxy(C1-6alkyl), C2-7alkoxycarbonyl(C1-6alkyl), aminocarbonyl(C1-4alkyl), aminocarbonyloxy(C1-4alkyl), amino(C1-4alkanoyloxy)(C1-4alkyl), amino(C2-9alkoxycarbonyl)(C1-4alkyl), C2-7alkylcarbonyl, C2-7alkoxycarbonyl, C1-6alkylthio, hydroxyC1-6alkylthio, C1-6alkoxy(C1-6alkylthio), C2-1 alkanoyloxy(C2-4alkylthio), C2-11alkanoyloxy(C2-4alkylsulphinyl), C2-11alkanoyloxy(C2-4alkylsulphonyl), aminocarbonyloxy(C2-4alkylthio), C2-11aminoalkanoyloxy(C2-4alkylthio), aminocarbonyloxy(C2-4alkylsulphinyl), aminocarbonyloxy(C2-4alkylsulphonyl), aminoalkanoyloxy(C2-4alkylsulphinyl), aminoalkanoyloxy(C2-4alkylsulphonyl), aminocarbonyl, C3-6alkenyl, C3-6alkynyl, haloC3-6alkenyl, haloC3-6alkynyl, hydroxyC3-6alkenyl, aryl(C1-6alkyl), hydroxylated aryl(C1-6alkyl), aryl(C3-6alkenyl), aryl(C3-6alkynyl), hydroxylated aryl(C3-6alkenyl), hydroxylated aryl(C3-6alkynyl), arylthio, heteroarylthio, aryl(C2-5alkoxycarbonylamino)(C1-4alkyl), halo, or cyano radical, or a radical of formula Q-(CH2—CH2—O)n—CO—O—CH2—, in which n is 1, 2, or 3 and Q is amino; or
7) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in vii) and R3 is a radical such that there is, at the 3-position, an amino acid D-MeAla; or
8) the radicals R1 to R11 and Z1 to Z11 are as defined in claim 4 in viii) and R3 is a radical such that there is, at the 3-position, an α-amino acid which is N-methylated at the α position and which has the D configuration.

### Claim 15 (depends on 14)

A method for preventing or treating a retrovirus infection or an associated syndrome, comprising administering to a mammal in need or desire thereof an effective amount of a cyclosporin derivative as defined in claim 14 in 1), 2), 3), 4), or 7).

### Claim 16 (depends on 15)

The method of claim 15, in which the retrovirus infection is AIDS (acquired immunodeficiency syndrome).

### Claim 17 (depends on 14)

A method for treating a chronic inflammatory disease or an autoimmune disease, comprising administering to a mammal in need or desire thereof an effective amount of a cyclosporin derivative as defined in claim 14 in 5).

### Claim 18 (depends on 14)

A method for preventing or treating an autoimmune disease or preventing rejection of a transplanted organ, comprising administering to a mammal in need or desire thereof an effective amount of a cyclosporin derivative as defined in claim 14 in 6) or 8).

### Claim 19 (depends on 14)

A method for treating inflammation, comprising administering to a mammal in need or desire thereof an effective amount of a cyclosporin derivative as defined in claim 14 in 6) or 8).

### Claim 20 (depends on 19)

The method of claim 19, in which the inflammation is an arthritis or a rheumatic disease.

### Claim 21 (depends on 14)

A method for treating schistosomiasis, filariasis, leishmaniasis, coccidioidomycosis, or malaria, comprising administering to a mammal in need or desire thereof an effective amount of a cyclosporin derivative as defined in claim 14 in 6) or 8).

### Claim 22 (depends on 1)

The process according to claim 1, wherein when Ri in formula (IIIb) is propenyl, the double bond exhibits a trans configuration.

### Claim 23 (depends on 13)

The process according to claim 13, wherein said cyclosporin derivative substituted at the 3-position is chosen from:
[(R)-2-aminoethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-methylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-ethylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-isopropylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-t-butylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-phenylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-benzylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-methyl-N-ethylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-methyl-N-allylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N-methyl-N-phenylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N,N-diisopropylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(N,N-diallylamino)ethylthio-Sar]3-cyclosporin A;
[(R)-3-aminopropylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methylamino)propylthio-Sar]3-cyclosporin A;
[(R) 3-(N-ethylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-isopropylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-t-butylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-phenylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-benzylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-ethylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-isopropylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-t-butylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-allylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-phenylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N-methyl-N-benzylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N,N-diethylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N,N-diisopropylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(N,N-diallylamino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(1-piperidyl)propylthio-Sar]3-cyclosporin A;
[(R)-4-(aminobutylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-ethylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-isopropylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-t-butylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-phenylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-benzylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-ethylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-isopropylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-t-butylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-allylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-phenylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N-methyl-N-benzylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N,N-dimethylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N,N-diethylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N,N-diisopropylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(N,N-diallylamino)butylthio-Sar]3-cyclosporin A;
[(R)-4-(1-piperidyl)butylthio-Sar]3-cyclosporin A;
[(R)-2-amino-2-methylpropylthio-Sar]3-cyclosporin A;
[(R)-2-(N,N-dimethylamino)-2-methylpropylthio-Sar]3-cyclosporin A;
[(R)-2-(N,N-diethylamino)-2-methylpropylthio-Sar]3-cyclosporin A;
[(R)-2-(1-piperidyl-2-methylpropylthio-Sar]3-cyclosporin A;
[(R)-3-amino-3-methylbutylthio-Sar]3-cyclosporin A;
[(R)-3-(N,N-dimethylamino)-3-methylbutylthio-Sar]3-cyclosporin A;
[(R)-3-(N,N-diethylamino)-3-methylbutylthio-Sar]3-cyclosporin A;
[(R)-3-(1-piperidyl)-3-methylbutylthio-Sar]3-cyclosporin A;
[(R)-2-(1-morpholino)ethylthio-Sar]3-cyclosporin A;
[(R)-2-(1-azetidino)ethylthio-Sar]3 -cyclosporin A;
{(R)-2-[1-(4-methylpiperazino)]ethylthio-Sar}3-cyclosporin A;
{(R)-2-[1-(4-phenylpiperazino)]ethylthio-Sar}3-cyclosporin A;
{(R)-2-[1-(4-benzylpiperazino)]ethylthio-Sar}3-cyclosporin A;
{(R)-2-[1-(4-methyl-1,2,3,6-tetrahydropyridyl)]ethylthio-Sar}3-cyclosporin A;
{(R)-2-[1-(4-phenyl-1,2,3,6-tetrahydropyridyl)]ethylthio-Sar}3-cyclosporin A;
[(R)-3-(1-morpholino)propylthio-Sar]3-cyclosporin A;
[(R)-3-(1-azetidino)propylthio-Sar]3′-cyclosporin A;
{(R)-3-[1-(4-methylpiperazino)]propylthio-Sar}3-cyclosporin A;
{(R)-3-[1-(4-phenylpiperazino)]propylthio-Sar}3-cyclosporin A;
{(R)-3-[1-(4-benzylpiperazino)]propylthio-Sar }3-cyclosporin A;
{(R)-3-[1-(4-methyl-1,2,3,6-tetrahydropyridyl)]propylthio-Sar}3-cyclosporin A;
{(R)-3-[1-(4-phenyl-1,2,3,6-tetrahydropyridyl)]propylthio-Sar}3-cyclosporin A;
[(R)-2-aminoethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-ethylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-isopropylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-t-butylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-phenylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-benzylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-ethylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-isopropylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-butylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-allylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-phenylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N-methyl-N-benzylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N,N-diethylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N,N-diisopropylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4 cyclosporin A;
[(R)-2-(N,N-diallylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(1-piperidyl)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-aminopropylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-ethylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-isopropylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4cyclosporin A;
[(R)-3-(N-tert-butylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]cyclosporin A;
[(R)-3-(N-phenylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-benzylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-ethylamino)propylthio-Sar]3- hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-N-isopropylamino)propylthio-Sar]3-[4′- hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-N-t-butylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-N-allylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-N-phenylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N-methyl-N-benzylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4 -cyclosporin A;
[(R)-2-(N,N-dimethylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N,N-diethylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N,N-diisopropylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N,N-diallylamino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(1-piperidyl)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-aminobutylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-ethylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-isopropylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-t-butylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-phenylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-benzylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-ethylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-isopropylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-t-butylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-allylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-phenylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N-methyl-N-benzylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N,N-dimethylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N,N-diethylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N,N-diisoproylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(N,N-diallylamino)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-4-(1-piperidyl)butylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A; [(R)-2-amino-2-methylpropylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N,N-dimethylamino)-2-methylpropylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(N,N-diethylamino)2-methylpropylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(1-piperidyl)-2-methylpropylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-amino-3-methylbutylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N,N-dimethylamino)-3-methylbutylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(N,N-diethylamino)-3-methylbutylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(1-piperidyl)-3-methylbutylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(1-morpholino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-2-(1-azetidino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-2-[1-(4-methylpiperazino)]ethylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-2-[1-(4-phenylpiperazino)]ethylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-2-[1-(4-benzylpiperazino)]ethylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-2-[1-(4-methyl-1,2,3,6-tetrahydropyridyl)]ethylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-2-[1-(4-phenyl-1,2,3,6-tetrahydropyridyl)]ethylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(1-morpholino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
[(R)-3-(1-azetidino)propylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-3-[1-(4-methylpiperazino)]propylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-3-[1-(4-phenylpiperazino)]propylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-3-[1-(4-benzylpiperazino)]propylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A;
{(R)-3-[1-(4-methyl-1,2,3,6-tetrahydropyridyl)]propylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A; and
{(R)-3-[1-(4-phenyl-1,2,3,6-tetrahydropyridyl)]propylthio-Sar}3-[4′-hydroxy-MeLeu]4-cyclosporin A.
